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Our purpose was to establish whether noninvasive measurement of
changes in 18F-fluoride metabolic flux to bone mineral (Ki) by PET/
CT can provide incremental value in response assessment of bone
metastases in breast cancer compared with SUVmax and SUVmean.
Methods: Twelve breast cancer patients starting endocrine treat-
ment for de novo or progressive bone metastases were included.
Static 18F-fluoride PET/CT scans were acquired 60 min after injec-
tion, before and 8 wk after commencing treatment. Venous blood
samples were taken at 55 and 85 min after injection to measure
plasma 18F-fluoride activity concentrations, and Ki in individual bone
metastases was calculated using a previously validated method.
Percentage changes in Ki, SUVmax, and SUVmean were calculated
from the same index lesions (#5 lesions) from each patient. Clinical
response up to 24 wk, assessed in consensus by 2 experienced
oncologists masked to PET imaging findings, was used as a refer-
ence standard. Results: Of the 4 patients with clinically progressive
disease (PD), mean Ki significantly increased (.25%) in all, SUVmax
in 3, and SUVmean in 2. Of the 8 non-PD patients, Ki decreased or
remained stable in 7, SUVmax in 5, and SUVmean in 6. A significant mean
percentage increase from baseline for Ki, compared with SUVmax and
SUVmean, occurred in the 4 patients with PD (89.7% vs. 41.8% and
43.5%, respectively; P , 0.001). Conclusion: After 8 wk of endocrine
treatment for bone-predominant metastatic breast cancer, Ki
more reliably differentiated PD from non-PD than did SUVmax and
SUVmean, probably because measurement of SUV underestimates
fluoride clearance by not considering changes in input function.
Key Words: breast cancer; bone metastases; heterogeneity, 18F-
fluoride PET/CT
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The bone-specific tracer 18F-fluoride is a marker of osteoblast
activity in metastatic bone deposits. Both sclerotic and lytic met-
astatic bone lesions are highly 18F-fluoride–avid (1) and show
increased blood flow and metabolic flux (plasma clearance) to
the bone mineral compartment (Ki), allowing quantification of
the regional kinetics of abnormal bone metabolism on 18F-fluoride
PET/CT (2). Ki is related to histomorphometric measures of bone
turnover (3,4), and its measurement by PET has been proposed as
a valuable and feasible method for measuring changes in regional
bone turnover as a result of treatment in skeletal metastases from
breast cancer (5) and has also been evaluated in assessing response
in bone metastases from prostate cancer (6). By accounting for
delivery and extraction of 18F-fluoride, Ki appeals as a more dis-
criminatory parameter for assessing treatment response of bone
metastases rather than static measures such as SUV (7,8). Al-
though SUV is one of the commonest and simpler methods for
quantifying 18F-fluoride PET studies, requiring only a short static
scan and thus averting the need for invasive arterial blood sam-
pling and lengthy dynamic scans, regional delivery and metabolic
activity may be affected by changes in tracer kinetics at other sites
in the body. Thus, Ki is a potentially more accurate and discrim-
inatory parameter because both the delivery (arterial input func-
tion) and the local bone metabolism (time–activity curve) are
measured over time to calculate kinetic indices of local bone
metabolism (9,10).
Most quantitative 18F-fluoride PET studies have been performed
using 60-min dynamic scans whereby the bone activity curve is
combined with an arterial input function and Ki is calculated using
the Hawkins 3-compartment model (11–15) or other simplified
methods such as the Patlak method (16–18). However, only one
dynamic scan can be acquired after a single injection of 18F-fluoride
with a limited field of view on the PET scanner, and the invasive
nature of arterial blood sampling and the requirement for trained
personnel make this procedure unappealing for routine use.
Different approaches that are simpler to implement have been
applied to avoid arterial cannulation (19–22) and allow multiple
lesions to be measured (23). For example, a semi–population-
based input function method has previously been proposed
whereby Ki is calculated by initially fitting a terminal exponential
to the measurements of venous plasma concentration and then add-
ing a population-based residual curve (24). The main advantages of
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this methodology are to allow calculation of Ki from static 18F-fluoride
PET scans in multiple lesions without the need for arterial sampling
and to allow a more physiologic measure of changes in bone turn-
over in response to treatment (23).
Previous osteoporosis studies have reported differences in SUV
and plasma clearance between cortical and trabecular bones
suggesting different effects of treatment at different sites of the
skeleton (15,25,26). One study reported a much higher mean per-
centage change in Ki than in SUV (24% vs. 3%) in the lumbar spine
in osteoporotic women treated with teriparatide, suggesting poten-
tially higher uptake of injected dose at other skeletal sites (15).
We hypothesized that measurement of Ki is feasible using a
static method with venous blood measurement and that Ki is more
discriminatory than SUVmax or SUVmean in treatment response
assessment. The aim of this study was to compare 18F-fluoride
Ki, derived from a static method, (27) with SUVmax and SUVmean
in assessing the response of breast cancer bone metastases to
endocrine therapy and to determine the level of correlation be-
tween the 2 methods. We also aimed to evaluate the effect of
endocrine therapy on Ki in nonmetastatic cortical and trabecular
sites in the skeleton.
MATERIALS AND METHODS
Participants
Twelve female breast cancer patients (mean age, 50.4 y; range, 40–
79 y) with de novo (5 patients, 20 lesions) or progressive bone me-
tastases (7 patients, 52 lesions) starting endocrine treatment were included.
Apart from 2 patients who had small-volume lung and liver metastases,
all other patients had bone-only disease. The endocrine treatments were
letrozole (n 5 7), tamoxifen (n 5 3), and everolimus/exemestane (n 5
2). 18F-fluoride PET/CT scans were acquired before and 8 wk after
starting treatment. Two experienced oncologists masked to the PET
findings determined clinical response (based on standard imaging, in-
cluding bone scans and CT, and on clinical assessment, including pain
scores, alkaline phosphatase, and carcinoma antigen 15-3) up to 24 wk
after the start of treatment or until progression, whichever came first.
This assessment was used as a reference standard. We categorized pa-
tients as having either clinically progressive disease (PD) or nonpro-
gressive disease (non-PD). We chose to include and assess patients with
partial response and stable disease together as non-PD because clinical
management rarely differs in these 2 groups.
The study was approved by a Research Ethics Committee and the
Administration of Radioactive Substances Advisory Committee, and
all patients gave written informed consent at the time of recruitment.
Blood Sampling
Venous blood samples (5 mL each) were acquired at 55 and 85 min
after injection of 18F-fluoride. Two 0.2-mL aliquots from each blood
sample were weighed and then counted on a 10-sample well counter
(2470 Wizard2; PerkinElmer) previously cross-calibrated with the
PET scanner using a standard calibration technique subject to daily
quality control. The calibration process used 18F-FDG mixed with
water in a 6-L phantom to a known activity concentration and scanned
on the PET scanner. Ten 0.2-mL samples were taken from the
phantom and counted on the well counter for 3 min, allowing the
calculation of a conversion factor between the scanner and well counter
measured in counts per second per activity concentration (kBq/mL).
Whole-blood samples were then centrifuged for 5 min (6,000 rpm),
and two 0.2-mL samples of plasma from each were also weighed and
then counted in the well counter. The resulting counts per minute were
converted to activity concentrations (kBq/mL) using a calibration factor.
18F-Fluoride PET/CT Image Acquisition and Reconstruction
18F-fluoride (mean, 2286 15 MBq) was injected intravenously, and
scanning commenced after an uptake time of 60 min. Images were ac-
quired from skull base to upper thighs with an axial field of view of 15.7
cm and an 11-slice overlap between bed positions, using a Discovery 710
PET/CT scanner (GE Healthcare). A low-dose CT scan (140 kV, 10 mA,
0.5-s rotation time, and 40-mm collimation) was performed at the start of
imaging to provide attenuation correction and an anatomic reference. The
PET scan duration was set to 3 min per bed position.
PET image reconstruction included standard scanner-based correc-
tions for radiotracer decay, scatter, randoms, and dead time. Emission
sinograms were reconstructed with a time-of-flight ordered-subset
expectation-maximization algorithm (2 iterations, 24 subsets), with a
256 · 256 matrix and a gaussian postreconstruction smoothing filter of
4 mm in full width at half maximum, available from the manufacturer
on the scanner front-end.
Image Analysis
On 18F-fluoride PET/CT, we defined PD as an increase by at least 25%
in Ki, SUVmax, or SUVmean. Non-PD included patients with a partial
response (.25% decrease in Ki, SUVmax, or SUVmean) or stable disease
(,25% increase or decrease), as adapted from the criteria of the European
Organization for Research and Treatment of Cancer, with our acknowl-
edgment that these criteria were originally described for 18F-FDG (28).
Up to 5 of the hottest (SUVmax $ 10) (29) and largest ($1 cm)
lesions were selected for analysis in each subject. SUV measurements
were normalized to body weight. The lesion regions of interest (ROIs)
were contoured on the static 18F-fluoride PET/CT scans using in-house
software. The ROIs were outlined semiautomatically using an initial
40% of the maximum tumor pixel threshold around each metastasis
followed by manual correction based on an oncologist and radiologist
working in consensus. Tumor volumes were measured from the PET
ROIs both at baseline and again at 8 wk after starting treatment. The same
ROIs were used to estimate Ki, SUVmax, and SUVmean in each lesion. Ki,
SUVmax, and SUVmean were also measured in nonmetastatic trabecular
(center of L1 lumbar vertebra) and cortical (upper femoral shaft, 1 cm
below the lesser trochanter) bone similar to the metastatic ROIs. If
L1 contained a metastasis, the nearest normal vertebra was used as a
nonmetastatic trabecular ROI. No patients had metastatic disease in
the subtrochanteric left femur.
TABLE 1
Comparison of Tumor Parameters at Baseline and at 8 Weeks
Baseline 8 wk Mean % change
Mean tumor volume Ki SUVmax SUVmean Mean tumor volume Ki SUVmax SUVmean Ki SUVmax SUVmean
6.8 0.067 35.1 18.8 6.6 0.08 38.3 20.8 35.1 16.0 17.2
Data are for 52 tumors. Units are cm3 for tumor volume, mL min−1 mL−1 for Ki, and g/mL for SUV.
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Ki Analysis
Values of Ki in metastases were calculated from the static scan.
Venous blood samples and a modified Patlak method of calculation
were used as previously described by Siddique et al. (27,30) by applying
an input function obtained by adding a population residual curve to the
exponential, obtained from the 2 venous blood samples taken 55 and
85 min after injection. The population arterial input function was ac-
quired from 10 postmenopausal women as described previously (19)
and in the supplemental data (31–34) (supplemental materials are avail-
able at http://jnm.snmjournals.org).
Ki, SUVmax, and SUVmean at baseline and at 8 wk, as well as percent-
age change in Ki, SUVmax, and SUVmean from baseline (in patients with
PD and non-PD), were used for statistical analyses.
Statistical Analysis
Changes in Ki, SUVmax, and SUVmean were expressed as percentage
change from baseline. Data that were normally distributed were ex-
pressed as a mean and SD and compared using the paired t test, and
data that were not normally distributed were log-transformed first,
allowing a normal distribution. Correlations between the changes in
Ki against SUVmax and SUVmean were evaluated using the Pearson
correlation coefficient. For all statistical tests, a P value of 0.05 or less
was considered statistically significant.
RESULTS
By the clinical reference standard, there were 4 patients with
clinical PD (20 lesions) and 8 with non-PD (32 lesions). The
values of Ki, SUVmax, and SUVmean at baseline (12 patients, 52
lesions) and at 8 wk (the same 52 lesions), and the percentage
change in Ki, SUVmax, and SUVmean, are shown in Table 1 and the
supplemental data.
Correlations were present between Ki and SUVmax and between
Ki and SUVmean at baseline (r 5 0.632 [P , 0.001] and r 5 0.784
[P, 0.001], respectively) and at 8 wk (r5 0.830 [P, 0.001] and
r 5 0.901 [P , 0.001], respectively) (Table 2).
In all patients on a per-lesion basis, a statistically significant
correlation was observed at 8 wk between percentage change in
Ki and percentage change in SUVmax (r 5 0.852, P , 0.001) and
between percentage change in Ki and percentage change in SUVmean
(r5 0.901, P, 0.001) (Fig. 1; Table 2). In PD patients, a statistically
significant correlation was observed at 8 wk between percentage
change in Ki and percentage change in SUVmax (r 5 0.811, P ,
0.001) and between percentage change in Ki and percentage
change in SUVmean (0.904, P , 0.001). In non-PD patients, a
statistically significant correlation was observed at 8 wk between
percentage change in Ki and percentage change in SUVmax (r 5
0.863, P , 0.001) and between percentage change in Ki and
percentage change in SUVmean (r 5 0.933, P , 0.001) (Table 2).
In all patients on a per-patient basis, a correlation was noted be-
tween mean percentage change in Ki and mean percentage change
in SUVmax (r 5 0.88, P , 0.001) and between mean percentage
change in Ki and mean percentage change in SUVmean (r 5 0.81,
P 5 0.001) (Fig. 2).
Measurements of Ki after 8 wk of endocrine therapy showed a
significant change in metastases from baseline, with an overall
mean increase of 35.1% (SD, 58.4%) for
Ki, compared with 16.0% (SD, 32.4%) for
SUVmax (P 5 0.005) and 17.2% (SD,
35.7%) for SUVmean (P 5 0.001) (Table
1). In patients with PD, the mean percent-
age increase was 89.7% (SD, 61.7%) for Ki,
compared with 41.8% (SD, 27.8%) for
SUVmax (P 5 0.001) and 43.5% (SD,
41.9%) for SUVmean (P , 0.001). In non-
PD patients, the mean percentage increase
was 11.0% (SD, 36.7%) for Ki, compared
with 6.2% (SD, 28.9%) for SUVmax (P 5
0.60) and 7.4% (SD, 27.5%) for SUVmean
(P 5 0.70). The mean percentage increase
in Ki was statistically significantly higher in
patients with PD than in patients with non-
PD (Ki 5 89.7% vs. 10.7%, P , 0.01), but
the same was not true for SUVmax (41.8%
vs. 6.2%, P 5 0.067) or SUVmean (43.5%
vs. 7.4%, P 5 0.153)) (Table 3).
FIGURE 1. Lesion analysis: Scatterplot for percentage changes in Ki against percentage
changes in SUVmax and SUVmean for PD and non-PD 8 wk after start of treatment.
TABLE 2
Correlation Between Ki and SUV at Baseline and at 8 Weeks
Correlation coefficient
% change
Comparison Baseline 8 wk All patients PD patients Non-PD patients
Ki vs. SUVmax 0.632 (P , 0.001) 0.830 (P , 0.001) 0.852 (P , 0.001) 0.811 (P , 0.001) 0.863 (P , 0.001)
Ki vs. SUVmean 0.784 (P , 0.001) 0.901 (P , 0.001) 0.901 (P , 0.001) 0.904 (P , 0.001) 0.933 (P , 0.001)
Data are for 52 tumors in 12 patients. Units are mL min−1 mL−1 for Ki and g/mL for SUV.
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On a per-lesion basis, Ki increased by more than 25% in 15 of 20
lesions (75%) (P 5 0.13), SUVmax in 11 of 20 lesions (55%) (P 5
0.13), and SUVmean in 8 of 20 lesions (40%) (P 5 0.02) in patients
with clinical PD. Ki, SUVmax, and SUVmean decreased or remained
stable in 27 of 32 lesions (84%) in patients with clinical non-PD. Ki,
SUVmax, and SUVmean were falsely positive (increased.25%) in 5 of
the 32 lesions in patients with clinical non-PD.
On a per-patient basis, of the 4 patients with clinical PD, mean
percentage change in Ki correctly identified all 4, mean percentage
change in SUVmax identified 3 of the 4, and mean percentage change
in SUVmean identified 2 of the 4. Of the 8 patients with clinical non-
PD, mean percentage change in Ki accurately identified 7 of the 8,
percentage change in SUVmax identified 5 of the 8, and percentage
change in SUVmean identified 6 of the 8. Ki was falsely positive in 1
of the 8 patients, SUVmax in 3 of the 8, and SUVmean in 2 of the 8.
The mean percentage change in Ki was
7.9 times higher in patients with high dis-
ease burden (n 5 7) (.5 bone metastases)
than in those with low disease burden (n 5
5) (48.8% vs, 6.2%, P5 0.017). There was
no significant difference in mean percent-
age change in SUVmax (18.6% vs. 10.9%,
P 5 0.22) or mean percentage change in
SUVmean (20.3% vs. 11.7%, P 5 0.12) be-
tween the 2 groups.
In normal cortical and trabecular non-
metastatic bone, the percentage change in
Ki was 21.7% versus 21.9%, respectively;
the percentage change in SUVmax was 4.8%
versus 212.6%, respectively; and the per-
centage change in SUVmean was 20.7%
versus 217.1%, respectively. There was a
statistically significant difference in Ki be-
tween baseline and 8 wk for cortical bone
(P 5 0.018) and a statistically significant difference in SUVmax be-
tween baseline and 8 wk for trabecular bone (P 5 0.050), but
other differences were not significant.
DISCUSSION
To our knowledge, this was the first study reporting an advantage
in measuring changes in metabolic flux (plasma clearance) of 18F-
fluoride to bone mineral (Ki) as an early, 8-wk, treatment response
marker for breast cancer bone metastases compared with the static
semiquantitative measures SUVmax and SUVmean. The methodology
allows estimation of the arterial input function by correcting a popula-
tion input function from venous plasma measurements. Together with
measurements from a static PET acquisition at 60 min after injection,
Ki can be estimated in any lesion within the static field of view (27).
TABLE 3
Comparison of Tumor Parameters at Baseline and at 8 Weeks in Individual PD and non-PD Patients
Baseline 8 wk % change
Patient type Patient no. Ki SUVmax SUVmean Ki SUVmax SUVmean Ki SUVmax SUVmean
PD 1 0.033 25.7 12.0 0.075 37.1 16.9 145.0 58.8 51.8
2 0.071 32.6 20.2 0.091 32.6 19.6 38.6 2.1 3.3
3 0.047 49.6 21.9 0.121 85.9 46.8 140.2 63.2 98.4
4 0.083 30.7 19.4 0.110 44.0 23.1 34.9 43.0 20.4
Non-PD 1 0.067 25.8 11.7 0.063 25.74 12.72 −4.7 −4.1 9.4
2 0.145 60.9 34.4 0.121 46.96 26.64 −14.5 −20.0 −20.7
3 0.078 37.6 21.7 0.076 26.70 16.72 −1.3 −28.0 −23.1
4 0.045 38.8 19.8 0.036 30.38 15.47 −19.8 −21.7 −21.8
5 0.051 26.1 14.4 0.051 27.35 15.40 5.4 12.3 11.4
6 0.040 12.4 25.3 0.079 37.59 18.77 97.5 48.2 50.8
7 0.055 25.0 14.8 0.063 34.73 18.31 15.6 32.5 23.0
8 0.059 27.6 13.4 0.051 23.68 14.02 10.1 30.1 30.5
P* P 5 ,0.01 P 5 0.067 P 5 0.153
*PD vs. non-PD.
PD data are for 20 tumors; non-PD data are for 32 tumors. Units are mL min−1 mL−1 for Ki and g/mL for SUV.
FIGURE 2. Patient basis: Scatterplot for percentage changes in Ki against percentage changes
in SUVmax and SUVmean for PD and non-PD 8 wk after start of treatment.
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We observed expected correlations between Ki and SUV parame-
ters at baseline and at 8 wk and between percentage change in Ki and
percentage change in SUV parameters in patients with PD or non-PD.
Compared with a clinical reference standard using data up to
24 wk, percentage change in Ki at 8 wk correctly predicted PD in
more patients and more lesions than either SUVmax or SUVmean (in
4, 3, and 2 of 4 patients, respectively, and in 15, 11, and 8 of 20
lesions, respectively) in patients with bone-predominant breast
cancer undergoing endocrine treatment. Ki correctly predicted non-
PD in more patients than SUVmax or SUVmean (in 7, 5, and 6 of 8
patients, respectively) but no difference was observed on a per-lesion
basis. The mean percentage increase in Ki was statistically signifi-
cantly higher in patients with PD than in patients with non-PD.
The metabolic flux of 18F-fluoride provides an assessment of
local bone mineralization taking into account the availability of
tracer (i.e., input function), whereas measurements of SUV ignore
possible changes in the input function. When plasma 18F-fluoride
concentration is reduced, either because of a high global avidity
of metastatic lesions or an increase in the metabolic activity of
the remaining normal skeleton, then SUV parameters may
underestimate mineralization in individual lesions. This possibility
is supported by our observations. First, patients with a higher
disease burden showed significantly greater changes in Ki than
patients with a low disease burden. Second, we observed an in-
crease in metabolic activity in the nonmetastatic skeleton at both
trabecular and cortical sites, presumably as an effect of endocrine
treatment. These changes were lower than those seen in metastases—
thus maintaining contrast between metastatic and normal skeleton—
but were greater when measured by Ki than by SUV parameters in
cortical bone.
The relatively small number of patients in this study limits
statistical comparisons, but this limitation was partly mitigated by
a larger number of lesions (n 5 52). Although measurement of Ki
shows advantages over SUVmax, false-positives caused by the flare
phenomenon remain a factor that must be considered, as previ-
ously described (35–37). Our observation of more than a 25%
increase in Ki in 5 of 32 lesions (in non-PD patients) might be
accounted for by this phenomenon. Nevertheless, the ability to
predict PD or non-PD after 8 wk of endocrine treatment remained
good in this cohort, especially using Ki, with all 4 of the PD
patients and 7 of the 8 non-PD patients being correctly predicted,
and Ki was a significantly better discriminator of PD from non-
PD. Some of the smaller metastases might have been susceptible
to partial-volume error, introducing potential bias, but we did not
attempt to correct for this. Percentage change, rather than absolute
values, of parameters was of primary interest, and partial-volume
errors would have been similar for each parameter given that
the same ROIs were used for calculations. Because the modified
Patlak method corrects for 18F-fluoride efflux from bone, errors
resulting from no direct measurement of backflow from
bone mineral (k4) would be minimal (23). The population input
function used in our method was derived from postmenopausal
women, and although these did not have metastatic breast cancer,
they did not have any other known skeletal disease and had a mean
age similar to our patient cohort (54.8 and 50.4 y, respectively). In
addition, it has previously been shown that precision errors in 18F-
fluoride PET skeletal static and kinetic parameters are relatively
small (coefficient of variation, 12%–14%) (38) and generally less
than the changes we observed in this series.
Prediction of PD is most important to the oncologist by allowing
an earlier transition to second- or third-line therapy while minimizing
potential toxicity from ineffective treatment. Patients with either stable
disease or a partial or complete response would normally have
treatment continued; it is therefore clinically relevant to include both
stable and responder groups together in this analysis.
A gold standard for predicting treatment response in bone
metastases is lacking in clinical practice. However, our clinical
reference standard was made as robust as possible by using standard
clinical data (imaging, biochemistry, tumor markers, and clinical
features) in consensus by 2 oncologists masked to the PET results
and with the time advantage of allowing assessment up to 24 wk.
CONCLUSION
This study has shown that measurement of 18F-fluoride meta-
bolic flux (Ki) in breast cancer bone metastases, using static 18F-
fluoride PET/CT with venous blood sample counts, is feasible and
may be more reliable in differentiating PD from non-PD than
semiquantitative SUV measures. In particular, the observed accu-
rate identification of PD is important and of clinical utility. These
preliminary results deserve further prospective validation in larger
patient groups under different therapy regimes.
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